7070 results for
Refine Your Search
Keaton
I was diagnosed with Hodgkin lymphoma (HL) in May of 2019. I first noticed something was wrong in January of that year when I noticed lumps in my neck…
Jelien
Jelien started showing signs in early July of 2018. She had bruises and cuts that were taking too long to heal. In November, she kept spiking fevers w…
Zariyah
Zariyah was diagnosed with acute lymphoblastic leukemia (ALL) on May 9, 2016. She had just turned three years old the previous November. She was immed…
Christopher Porter
Dr. Porter is an Associate Professor of Pediatrics and holds the Paul Amos Chair for Pediatric Oncology Research. He is a pediatric hematologist-oncol…
Targeting Siglec15 to promote immune response to malignant B cells
The goal of this project is to explore a novel immunologic therapeutic target for hematologic malignancies, SIGLEC15 (Sig15). The central hypothesis i…
Investigating anti-neoplastic effects of beta blockers in multiple myeloma
Multiple myeloma (MM) relies on the bone marrow (BM) niche to progress to refractory disease. We found that beta blockers alter BM niche elements fost…
Peripheral blood-based disease monitoring by mass spectrometry in patients with multiple myeloma
The present project will investigate the ability of quantitative immune precipitation mass spectrometry (QIP-MS) to anticipate relapsed or progressive…
Alana
My name is Alana, and I’m 17 years old. Here is my story. On June 29, 2021, I was out having dinner with my family, and my smartwatch told me that my …
Noemí Puig Morón
Noemi Puig, MD, PhD earned her medical degree from the Universidad Complutense in Madrid and she completed her residency in Internal Medicine and Hema…
Targeted combination therapies for leukemia with NUP98 translocations
Leukemia patients with chromosomal translocations of the Nucleoporin (NUP98) gene suffer from very poor prognosis. In this project we will identify ne…
Joachim Yahalom
MD- Hebrew University, Jerusalem. Residencies and Fellowships in Clinical and radiation Oncology in Israel and Memorial Sloan-Kettering. Armored Briga…
Impact of sublethal radiation dose on tumor response, microenvironment and the immune system
Extremely low dose radiation can improve blood cancer outcomes. But the mechanisms of how sublethal radiation (SRT) affects tumors, the microenvironme…
Suzanne Lentzsch
I’m a Professor of Medicine and the Director of the Multiple Myeloma and Amyloidosis Program at Columbia University. I received my medical and doctora…
Targeting the MMP-13/PD-1H signaling axis for multiple myeloma bone disease and immunosuppression
Multiple myeloma is an incurable blood cancer complicated by bone diseases and compromised immune system. Our work indicated that checkpoint inhibitor…
Daniel Thomas
Associate Professor Daniel Thomas is a Stanford-trained physician scientist who leads the Myeloid Metabolism Laboratory in the Precision Medicine Them…
Identification and Molecular Analysis of Pre-Myelofibrotic Stem Cells
Myelofibrosis is a severe myeloproliferative neoplasm with no known cure. We have obtained unique insights into the underlying mechanisms responsible …
Ravi Bhatia
Ravi Bhatia, MD is Professor in the Department of Medicine, the John G. Kelton, M.D., Endowed Chair and Director of Research in the Division of Hemato…
Prediction and prevention of therapy-related myeloid neoplasms following autologous transplantation
The proposed studies will identify alterations in hematopoietic regulation that predict for risk for therapy-related myeloid neoplasm (TMN) and improv…
Randall Davis
A graduate of Boston University, Dr. Davis completed medical school at the University of Alabama School of Medicine, where he also served his internsh…
Immunotherapeutic Targeting of FCRL1 in CLL
Evolving insights into the B cell-restricted FCRL1 surface protein reveal that it integrates with critical signaling pathways and is a promising immun…
Jane Oliaro
Professor Jane Oliaro is an internationally recognized cancer immunologist motivated to translate scientific discoveries into the clinic.
Improving CAR-T cell therapy outcomes for patients with for aggressive lymphoma and multiple myeloma
Despite the promise of CAR-T cell immunotherapy for patients with lymphoma and multiple myeloma, a significant proportion of patients fail to respond …
Dissecting the biology and exploiting the dependency of myeloma cells on P300/CBP
In recent work of our collaborating labs, the protein acetyltransferases P300 and CBP emerged as potent and preferential dependencies for multiple mye…
Richard Lock
Dr. Lock is investigating mechanisms of glucocorticoid resistance in pediatric acute lymphoblastic leukemia (ALL) and tests potential new treatments f…
Therapeutic targeting of T-cell acute lymphoblastic leukemia using an AKR1C3-activated prodrug
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy that is exceptionally difficult to cure after relapse. We have previously show…